Barely Significant
← all excerpts

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.

NPJ Breast Cancer · 2023 · PMC10199936 · PMID 37210417

Europe PMCDOI
1
hedged sentence
0.2000
closest p · 4.0× alpha
0.2000
boldest claim

The sentences

moderately significantp < 0.2not close (p > 0.1)
Multivariate Cox proportional hazard survival analysis To assess the multivariate associations between risk factors and PFS, prior fulvestrant and all factors that had moderately significant ( p < 0.2) univariate associations with PFS were included in a multivariate CoxPH model.

also in 2,182 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.